Leflunomide
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Leflunomide |
| DrugBank ID | DB01097 |
| Brand Names (EU) | Arava, Leflunomide medac |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.97% |
Approved Indication (EMA)
Leflunomide is indicated for the treatment of adult patients with: active rheumatoid arthritis as a ‘disease-modifying antirheumatic drug’ (DMARD); active psoriatic arthritis. Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects. Moreover, switching from leflunomide to another
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | rheumatoid arthritis | 99.97% | DL |
| 2 | brachydactyly-syndactyly syndrome | 99.93% | DL |
| 3 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 99.93% | DL |
| 4 | indolent plasma cell myeloma | 95.47% | DL |
| 5 | plasma cell myeloma | 95.16% | DL |
| 6 | myeloid leukemia | 92.99% | DL |
| 7 | Meester-Loeys syndrome | 86.55% | DL |
| 8 | ganglioneuroblastoma (disease) | 76.30% | DL |
| 9 | WHIM syndrome | 75.88% | DL |
| 10 | scalp dermatosis | 73.87% | DL |
| 11 | vertebral anomalies and variable endocrine and T-cell dysfunction | 72.25% | DL |
| 12 | retroperitoneal neoplasm | 71.43% | DL |
| 13 | obsolete susceptibility to ischemic stroke | 70.51% | DL |
| 14 | neuroblastoma | 64.84% | DL |
| 15 | gout | 63.94% | DL |
| 16 | polydipsia | 62.14% | DL |
| 17 | congenital temporomandibular joint ankylosis | 61.70% | DL |
| 18 | cholangiocarcinoma, susceptibility to | 60.31% | DL |
| 19 | anuria | 59.24% | DL |
| 20 | osteoarthritis susceptibility | 57.89% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.